Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This combination intervention consists of a medical device, the Arabin cervical pessary, and a hormonal pharmaceutical, vaginal progesterone. It is specifically being evaluated for the prevention of preterm birth in women with twin pregnancies and an asymptomatic short cervix. The Arabin pessary is a silicone ring designed to provide mechanical support to the cervix and redistribute the weight of the uterus, while vaginal progesterone (typically 400mg micronized) acts as a hormonal supplement to maintain uterine quiescence and inhibit cervical ripening. The combination is the focus of the PRECEPT trial (Progesterone and Cervical Pessary in Twins), a randomized controlled study led by Mario Henrique Burlacchini de Carvalho.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Arabin Pessary + vaginal progesterone.